--- a
+++ b/clusters/3009knumclusters/clust_28.txt
@@ -0,0 +1,1916 @@
+Absolute neutrophil count (ANC) > 1500/mm^3 =< 2 weeks prior to randomization
+Absolute neutrophil count (ANC) >= 1 x 10^9/L within 30 days of day 1 of study
+Peripheral absolute neutrophil count (ANC) >= 750/mm^3
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3; obtained within 14 days prior to study entry
+Must have absolute neutrophil count ? 1.5 x 10^9/L within 14 days prior to randomization.
+Absolute neutrophil count (ANC) < 750/?L
+Absolute neutrophil count (ANC) ? 1,500/mm3
+Absolute lymphocyte count (ALC) ? 500/mm3
+Absolute neutrophil count (ANC) > 1.5 cells/mm^3
+Absolute neutrophil count (ANC) >= 1.5 10^9/L, within 28 days prior to administration of study treatment
+* Peripheral absolute neutrophil count (ANC) >= 1000/mm^3
+For patients with solid tumors without known bone marrow involvement: peripheral absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mL within 28 days prior to registration
+Within 6 weeks prior to randomization: Absolute neutrophil count (ANC) must be >= 1200/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) > 1500 mm^3, must be obtained within 8 weeks prior to screening for protocol therapy
+ELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): Absolute neutrophil count (ANC) > 1500 mm^3
+STEP I: Absolute neutrophil count >= 1000 cells/mm^3 (obtained within 28 days prior to randomization)
+Absolute neutrophil count (ANC) > 1,000/mm^3
+Absolute neutrophil count (ANC) >= 1,200/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count >= 1,500/mm^3 must be obtained =< 7 days prior to protocol registration
+Absolute neutrophil count >= 1,500/mm^3
+Within 2 weeks prior to registration: Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1500 mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count >= 1,500/mm^3 within 4 weeks prior to randomization
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L measured within 28 days prior to randomization
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Within 60 days prior to registration on study: Absolute neutrophil count (ANC) >= 1,500/mm^3
+Within less than or equal to 14 days prior to registration: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Within 14 days of registration: Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count >= 1500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Obtained within 28 days prior randomization: absolute neutrophil count (ANC) must be >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
+RE-REGISTRATION ELIGIBILITY CRITERIA (STEP 2): Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,500/mm^3 obtained =< 21 days prior to registration
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L within 14 days prior to registration.
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3, within 21 days prior to registration
+Absolute neutrophil count (ANC) >= 1,800 cells/mm^3
+Absolute neutrophil count (ANC) >= 1,800 cells/mm^3
+Absolute neutrophil count (ANC) >= 500 cells/mm^3
+Absolute neutrophil count (ANC) >= 750/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Anti-cancer agents not known to be myelosuppressive (e.g. not associated with reduced platelet or absolute neutrophil count [ANC] counts): >= 7 days after the last dose of agent
+Absolute neutrophil count (ANC) >= 1,200 cells/mm^3, within 21 days prior to study entry
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count ? 1,500/µL
+Absolute neutrophil count (ANC) > 1,000
+Obtained within 14 days prior to treatment start: Absolute neutrophil count >= 1.5 × 10^9/L
+For patients with solid tumors, the following criteria apply: a. Hemoglobin ? 9.0 g/dl, b. Absolute lymphocyte count ? 1.0 x 10^9/L, c. Absolute neutrophil count ? 1.5 x 10^9/L, d. Platelets ? 100.0 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L, measured within 28 days prior to administration of study treatment
+Within 10 days of treatment initiation: Absolute neutrophil count (ANC) >= 1000 cells/mm^3 (or >= 750 in subjects with bone marrow involvement)
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1.2 x 10^9/L
+Absolute neutrophil count (ANC) >= 1000/mm^3, independent of growth factor support, documented within 14 days of registration
+Absolute neutrophil count >= 1,000/mm^3
+Hematology: Absolute neutrophil count (ANC) >1,500 cells/mm3, platelet count >100,000 cells/ mm.cu. and hemoglobin > 9 g/dL
+Absolute neutrophil count (ANC) >= 1.5 X 10^9/L
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) greater than or equal to 750/mm^3
+Absolute neutrophil count >= 1.5 x 10^9/L.
+Absolute Neutrophil Count (ANC) ? 1,000/?L
+Absolute neutrophil count (ANC) ? 1.5 x 10^9/L (1500/mm3)
+Absolute neutrophil count ? 1000/?L, with or without cytokine support
+Absolute neutrophil count >= 1.0 x 10^9 cells/ L
+Absolute neutrophil count (ANC) ? 1.5 × 10e3/µL
+Absolute neutrophil count (ANC) >/= 1.5 × 109/L
+Obtained =< 21 days prior to registration: Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count < 1 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,500/mm^3 (=< 28 days prior to registration)
+Absolute neutrophil count (ANC) >= 1.5 K/mm^3 obtained within 14 days prior to registration
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count > 1500/µL
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3 (1.5 x 10^9/L) must be met within 28 days of cycle 1 day 1 (C1D1)
+Obtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) ? 1,000 cells/mm3 (1.0 x 109/L)
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) ? 1500 cells/?L
+Absolute myeloblast count ?20,000/mm^3;
+Absolute neutrophil count (ANC) at least 1,000/mm3
+Any of the following clinical laboratory values at the time of enrollment: (1) Absolute neutrophil count (ANC) <800/µL or (2) Platelets < 50,000/µL
+INCLUSION CRITERIA FOR SECOND-LINE THERAPY: Absolute neutrophil count (ANC) >= 1,500/mm^3
+INCLUSION CRITERIA FOR THIRD-LINE THERAPY: Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) ? 1000/mm3 2) Insufficient hepatic and renal function at screening:
+Absolute neutrophil count >= 1.0 x 10^9/L
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) ? 1000 cells/mm3
+Absolute lymphocytes count ? 800 cells/mm3
+Absolute neutrophil count < 1.0 x 109/L
+Absolute neutrophil count >= 1,000/mm^3
+Absolute neutrophil count > 500/mm3
+Absolute neutrophil count (ANC) > 1500 cells/mm^3
+Absolute neutrophil count >= 1.5 x 10^9/L
+Peripheral absolute neutrophil count ? 1.5 × 10^9/L
+Absolute neutrophil count >= 1,000/mm^3
+Absolute neutrophil count (ANC) ? 1,500/mL
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
+Absolute neutrophil count (ANC) 1500/mm^3 within 3 weeks prior to study registration; blood transfusion to meet the inclusion criteria will not be allowed
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,000/mm^3, performed within 14 days of treatment initiation
+Absolute neutrophil count (ANC) ? 1000/mm3;
+Absolute neutrophil count ?1.5 x 109/L
+Absolute neutrophil count (ANC) >= 1.5 X 10^9/L within 14 days of starting cycle 1 day 1 treatment
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+absolute neutrophil count (ANC) ? 1.5 x 109/L and platelet count ?100 x 109/L
+Absolute neutrophil count (ANC) >= 1,000/mm^3 and
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil >= 1,500 cells/mm^3
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count >= 1.5 × 10^9/L
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute neutrophil count ?1500/µL.
+Serum hemoglobin ? 9 g/dL; absolute neutrophil count ? 1.5 x 109/L; platelets ? 100 x 109/L.
+Absolute neutrophil count (ANC) > 1,000 cells/dL (1.0 x 10e9/L) (growth factor cannot be used within the previous 7 days)
+Hematology Hemoglobin ? 9 g/dL (SI Units: 90 g/L) Platelet count < 75000/mm3 Absolute neutrophil count (ANC) < 1500/mm3
+Absolute neutrophil count (ANC) >= 1.0 × 10^9/L
+Absolute neutrophil count (ANC) ?1,500/mm3;
+Absolute neutrophil count (ANC) greater than or equal to 1500/µL
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count >= 1.0 × 10^9/L
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Hematologic: Absolute neutrophil count (ANC) ?1.5 x 10^9/liter (L), platelets ? 100 x 10^9/L, and hemoglobin ? 8 gram/deciliter (g/dL).
+Absolute neutrophil count >= 1,000/mm^3
+Absolute neutrophil count >= 1 x 10^9/L
+Absolute neutrophil count >= 1500/mm^3
+Absolute Neutrophil Count (ANC) > 1,500/µL
+Absolute neutrophil count > 500/mm^3
+Absolute neutrophil count >= 1500 per mm^3
+Absolute neutrophil count >= 1000 cells/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
+Absolute neutrophil count (ANC) >= 1500 unless due to direct bone marrow involvement of disease
+Absolute neutrophil count (ANC) >= 1,800 cells/mm^3
+Absolute neutrophil count (ANC) >= 1,800 cells/mm^3
+Absolute Neutrophil Count (ANC) greater than or equal to 1 x 10 to the ninth/Liter
+Absolute neutrophil count (ANC) > 500
+Absolute neutrophil count (ANC) <2,000/mm3
+Absolute neutrophil count (ANC) >= 1500 obtained =< 14 days prior to registration
+Absolute neutrophil count (ANC) ? 1500/mm^3
+Have an absolute neutrophil count (ANC) ?1.0 × 109/L.
+Absolute neutrophil count >= 1.0 x 10^9/L
+Within 10 (except as noted) days of planned treatment initiation: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500 per mm^3)
+Absolute neutrophil count > 1.5 x 10^9/L
+Absolute neutrophil count >= institutional lower limit
+Absolute neutrophil count (ANC) ? 1000 cells/?L
+Absolute neutrophil count (ANC) ?1.5 × 10?9/Liter (L);
+Absolute neutrophil count (ANC) ? 1,000/mm^3
+Absolute neutrophil count (ANC) ?1500/millimeters cubed (mm^3) (?1.5 × 10^9/Liters [L]);
+ENROLLMENT TO THE DOSE ESCALATION, EXPANSION AND PART II: Absolute neutrophil count >= 1,500 mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3 or >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1,000/mm^3
+absolute neutrophil count: ? 1.5 x 109/L
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,000/mm^3 \r\n* Exception: unless documented bone marrow involvement by lymphoma
+Obtained =< 2 weeks prior to registration: Absolute neutrophil count >= 1500/mm^3
+Obtained within 28 days prior to registration: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1,500/mm^3 within 14 days of enrollment to trial
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count >= 1500/mm^3
+and absolute neutrophil count (ANC) ? 1.5 × 109/L
+Peripheral absolute neutrophil count (ANC) >= 1000/mm^3
+Peripheral absolute neutrophil count (ANC) >= 1000/mm^3
+Peripheral absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1,000/mm^3 before starting therapy
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 obtained within 30 days prior to registration
+Absolute neutrophil count (ANC) > 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3 (1.5 x 10^9/L)
+Absolute neutrophil count of >500/µL
+Peripheral absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count >= 1.5 x 10^9/L, determined within 14 days of registration
+Absolute neutrophil count < 1.5 x 109/L.
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1000 cells/mm^3 (1.0 x 10^9/L) at least 3 weeks prior to screening unless attributable to disease; ANC > 500 cells/mm^3 is permissible if due to disease
+Absolute neutrophil count >= 1.5 x 10^9/L
+Within 28 days of study registration: Absolute neutrophil (segmented and bands) count (ANC) >= 1.0 x 10^9/L
+Within 28 days of study registration: Absolute lymphocyte count (ANC) >= 4.0 x 10^8/L
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) ? 1.0 x 10^9/L
+Obtained =< 35 days prior to registration: absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count ?1,000/mm3 without growth factor use ? 7 days prior to treatment (cycle 1 day 1, C1D1)
+Absolute neutrophil count (ANC) ? 1,500 cells/mm3
+Absolute neutrophil count ? 1.5 × 109/L (without myeloid growth factors within 1 week of study entry)
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count > 750 cells/mm^3 (0.75 x 10^9/L)
+Absolute neutrophil count (ANC) >= 1500
+Absolute neutrophil count >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1,800 cells/mm^3
+Absolute neutrophil count >= 1.0 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500 per mm^3)
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L without growth factor support, at the screening visit
+Absolute neutrophil count < 1.5 x 10 (exp9)/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9
+Absolute neutrophil count >= 1000/mm^3 (performed within 14 days of treatment initiation)
+Absolute neutrophil count (ANC) ?1.5×10?/L
+absolute Neutrophil Count (ANC) ? 1500 mm3, platelets ? 100,000/mm3, hemoglobin ? 9 g/dL,
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
+Absolute neutrophil count >= 1,000/mL
+Platelet count ? 100 × 109/L, hemoglobin ? 9.0 g/dL and absolute neutrophil count (ANC) ? 2.0 × 109 /L.
+Absolute peripheral blood myeloblast count greater than 20,000/mm3
+Absolute neutrophil count (ANC) >= 1000/mm^3, obtained =< 14 days prior to registration
+Absolute neutrophil count (ANC) > 1500/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3 (1.5 x 10^9/L)
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count ?1.0×109/L
+Absolute neutrophil count (ANC) >= 1.5 x10^9/L
+Platelet count > 100000 /mm3, hemoglobin (Hb) > 8 g/dL, absolute neutrophil count (ANC) 1500/mm3; the patient cannot be transfused in order to meet study entry criteria
+Platelets ? 50 x 10^9/L; Hb ? 8.0 g/dL; absolute neutrophil count (ANC) ? 1.0 x 10^9/L
+Absolute neutrophil count (ANC) > 1500 cells/mm^3
+Absolute neutrophil count (ANC) ?1.5 x 109/L;
+Absolute neutrophil count > 1000/mm3,
+Absolute neutrophil count (ANC) >= 1500/mm^3 is necessary; blood transfusion to meet the inclusion criteria will not be allowed
+Absolute neutrophil count (ANC) <1.5 x 109/L
+Absolute lymphocyte count (ALC) >= 500/ mm^3
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Neutrophil count >= 1.0 x 10^9/L
+Absolute neutrophil count >= 0.5 x 10^9/L (obtained =< 14 days prior to registration)
+Absolute neutrophil count (ANC) >= 1500/mm^3 obtained =< 28 days prior to registration
+Absolute neutrophil count > 1,000 cells/mm^3 (1.0 x 10^9/L)
+Absolute neutrophil count >= 1,000/mm^3
+Absolute Neutrophil Count (ANC) ? 1.5 x 10?/L.
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) ? 1,500 cells/?L,
+Absolute neutrophil count greater than 1000/mm^3 without support of filgrastim
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) > 1500/mm^3
+Absolute neutrophil count (ANC) > 1000/mm^3.
+Absolute neutrophil count (ANC) of >= 1.0 x 10^9/L
+Absolute neutrophil count >= 750 prior to treatment
+Neutrophil count >= 1.5 x 10^9/l
+Absolute neutrophil count (ANC) > 1000
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L without growth factor support
+Absolute neutrophil count >1,500/mm3
+Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) ?1.25 x 109/L
+Peripheral absolute neutrophil count (ANC) of at least 1,000/L
+Absolute neutrophil count >= 1,000/dL
+Absolute neutrophil count >= 750/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Obtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count >= 1500/mm^3
+Stable engraftment, as defined by absolute neutrophil count (ANC) >= 1000/mm^3 and platelets >= 25,000/mm^3
+Patients must have absolute neutrophil count (ANC) >= 500 cells/L (0.5 x 10^9/L)
+Absolute neutrophil count (ANC) >1,800 cells/mm3.
+Absolute neutrophil count (ANC) >= 1.5 K/mm^3
+PART I: Absolute neutrophil count (ANC) >= 1000 cells/mm^3
+PART I: Absolute lymphocyte count (ALC) >= 300 cells/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Peripheral absolute neutrophil count (ANC) >= 750/mm^3
+Absolute neutrophil count (ANC) >= 1,000/?l
+Absolute neutrophil count < 1.5 x 10^9/L
+Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC): >= 750/mm^3, must be at least 7days after last dose of growth factor
+Absolute neutrophil count greater than 1000/mm^3 without support of filgrastim
+Absolute neutrophil count (ANC) >= 1.5K/mm^3
+Absolute neutrophil count >= 1.5 x 10^9/L
+Within 14 days of randomization: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 × 10^9/L.
+Peripheral absolute neutrophil count (ANC) >= 1000/mm^3.
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count > 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) >= 1000 per mm^3 obtained within 14 days prior to initiating study treatment.
+Absolute neutrophil count (ANC) >= 1.5 × 10^9/L.
+Should be performed within 10 days of treatment initiation: absolute neutrophil count (ANC) ? 1.5 x 10^9/L (?1500 per mm^3)
+Absolute neutrophil >= 1,500 cells/mm^3
+ARM I&II: Absolute neutrophil count (ANC) > 1500/mm^3
+Absolute neutrophil count (ANC) > 1500/l
+Absolute neutrophil count ?1500/mm3
+Obtained ? 14 days prior to registration: Absolute neutrophil count (ANC) ? 1000/mm^3
+Absolute neutrophil count (ANC) < 1000/mm^3, per principal investigator (PI) discretion if thought to be related to underlying myeloma
+Absolute neutrophil count < 1000 cells/mm^3. No growth factors allowed within 1 week of enrollment
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L.
+Absolute neutrophil count (ANC) ? 1.0 x 10^9/L
+Absolute neutrophil count (ANC) ? 1,000 cells/mm3 (1.0 x 109/L) (Growth factors cannot be used within 10 days (14 days for pegfilgrastim) prior to initiation of therapy)
+Absolute neutrophil count > 1000/mm^3 without the support of growth factors
+Absolute neutrophil count (ANC) >= 1,000 cell/mm^3 without growth factor support, obtained =< 14 days prior to registration
+Absolute neutrophil count (ANC) ? 1,000 cells/mm^3
+Absolute neutrophil count (ANC) ?1,000/µL
+Neutrophil count of > 1500/mm^3
+Absolute neutrophil count >= 1.0 x 10^9/L
+Absolute neutrophil count >= 750/mm^3
+Absolute neutrophil count (ANC) less than 1500/mm^3
+Absolute neutrophil count ? 1000/mm^3, unless due to disease involvement in the bone marrow
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Obtained within 28 days prior to registration: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Within 7 days of enrollment and with 24 hours (h) of starting lymphodepleting chemotherapy: Absolute neutrophil count (ANC) >= 1000/mm^3.
+Within 28 days prior to registration: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1,000/mm^3, performed within 14 days prior to day 1 of protocol therapy\r\n* Filgrastim can be given prior to enrollment to achieve target ANC >= 1000/uL
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (in absence of blood transfusion).
+Absolute neutrophil count (ANC) >= 1,500 / ml obtained =< 14 days prior to study initiation
+STRATUM A: Absolute neutrophil count (ANC) >= 1000/mm^3 without growth factor support within 7 days of the test
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L.
+Absolute neutrophil count (ANC) >= 1 x 10^9/L
+Absolute neutrophil count >= 1 X 10^9/L
+Absolute neutrophil count (ANC) >= 1500/mm^3 (measured within 28 days of registration)
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count <1.5 x 109/L
+Absolute neutrophil count (ANC) ?1.0 × 10^9/L (Grade ?2).
+Peripheral absolute neutrophil count (ANC) ? 1000/mm3 and
+Absolute neutrophil count (ANC) ? 1.0 x 109/L
+Absolute neutrophil count greater than 1000/mm^3 without support of filgrastim
+Obtained within 21 days prior to cycle 1, day 1: absolute neutrophil count (ANC) >= 1 x 10^9/L
+Absolute neutrophil count (ANC) >= 1000/mm^3 independent of growth factor support
+Absolute neutrophil count (ANC) =< 1.0
+Absolute neutrophil count >= 1000/mm^3
+Absolute neutrophil count (ANC) > 1.5 k/cumm
+COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Absolute neutrophil (ANC) >= 1,500/mm^3 (>= 1.5 X10^6/L)
+COHORT 2: TRIPLE NEGATIVE BREAST CANCER: Absolute neutrophil (ANC) >= 1,500/mm^3 (>= 1.5 X 10^6/L)
+COHORT 3: ENDOMETRIAL CANCER: Absolute neutrophil (ANC) >= 1,500/mm^3 (>= 1.5 X 10^6/L)
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Peripheral absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) ? 1.0 x 10^9/L
+Absolute neutrophil count (ANC) ?750 cubic millimeters (mm³)
+Absolute neutrophil count (ANC) > 750 cells/mm^3 within 90 days prior to randomization
+Obtained within 28 days prior to registration: absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) ? 1,500
+Absolute neutrophil count (ANC) ? 1,000/mm^3
+Absolute lymphocyte count (ALC) ? 300/mm^3, and absolute number of CD3+ T cells > 150/mm^3
+Absolute neutrophil count (ANC) > 1.5 x 10^9/L (> 1500 per mm^3)
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) ? 1.5 x 10^9/L.
+Absolute neutrophil count >= 1.5 x 10^9/L
+Within 4 weeks of day 1: Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) > 750
+Absolute neutrophil count (ANC) ? 1.5 × 10^9/L obtained ? 14 days prior to randomization
+Adequate hematologic function as indicated by i. Absolute neutrophil counts (ANC) ? 1,500/mm3 ii. Hemoglobin (Hgb) ? 8.0 g/dL iii. Platelet count ? 100,000/mm3
+Absolute neutrophil count (ANC) < 1000/mm^3
+Absolute neutrophil count (ANC) > 1,000/mm^3 independent of growth factor support
+Absolute neutrophil count (ANC) >= 1000/mm^3 obtained =< 14 days prior to registration
+Absolute neutrophil count (ANC) >= 1.5 X 10^9/L
+Absolute neutrophil count >= 1,000/mm^3
+Absolute neutrophil count (ANC) ? 1.5 × 10^9/L
+Absolute neutrophil count >= 500/mm^3
+Absolute neutrophil count (ANC) ? 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count > 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) >= 1.5 x 10^9 /L
+Obtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count >= 1000 cells/mm^3 within 14 days of study registration
+Absolute neutrophil count (ANC) ? 1,500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute peripheral neutrophil count (ANC) > 1,000.
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Obtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500 per mm^3)
+Within 7-10 days of study drug administration: Absolute neutrophil count >= 1000/mm^3
+Absolute lymphocyte count ? 400/mm^3 within 10 days prior to “on study” status
+Absolute neutrophil count (ANC) ? 1,000/mm^3 within 10 days prior to “on study” status
+Absolute neutrophil count >= 1.5 x 10^9 cells per L
+Absolute neutrophil (ANC) count greater than 1000/ µL
+Within 7 days prior to administration of study treatment: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (unless due to bone marrow infiltration by tumor, in which case ANC > 1,000/mm^3 is allowed).
+Absolute neutrophil count (ANC) >= 1.5 k/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (> 1500 per mm^3)
+Peripheral Absolute neutrophil count (ANC) ? 1000/mm33
+Absolute neutrophil count ? 1,500/?L
+Absolute neutrophil count (ANC) >= 1,000 cells/mm^3 (1.0 x 10^9/L) must be met during screening (within 21 days) and also prior to study drug administration on cycle 1 day 1
+Absolute neutrophil count (ANC) ? 1.5 × 109/L
+Peripheral absolute neutrophil count (ANC) ?1.0 × 10^9/liter (L).
+Absolute neutrophil count (ANC) >= 1.5 K/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count >= 1.2 x 10^9/L
+Subjects not below specific total neutrophil count.
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L or at least 1500/mm^3 or at least 1.5 x 10^9/L
+Absolute neutrophil count >= 1,500/mm^3
+Within 14 days of the first dose of study drug: Absolute neutrophil count >= 1,500/·L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L.
+Within 7 days (+ 3 day window) of enrollment: Absolute neutrophil count (ANC) >= 1.0 x 10^9/L (> 1000 per mm^3)
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500 per mm^3)
+Absolute neutrophil count (ANC) >= 1,500/mm^3, at the time of enrollment
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (> 1500 per mm^3).
+Obtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1000/mm^3
+have adequate hematologic function, defined as having a hemoglobin ?8g/dL, an absolute neutrophil count (ANC) ?1.0 × 109/L, and platelet count ?75.0 x 109/L;
+Absolute neutrophil count (ANC) >= 1,000 cells/mm^3 without growth factors within 1 week of the initiation of treatment
+Absolute neutrophil count (ANC) ? 1.5 × 10^9/L
+Absolute neutrophil count > 1.5 x 10^9 cells/mm^3
+Obtained =< 28 days prior to registration: Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9 cells/mL
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) >1,500 /mm3;
+Absolute neutrophil count (ANC) ? 1500/?L
+Absolute neutrophil count >= 1,000/microliter
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Obtained within 14 days prior to the first study treatment (cycle 1, day 1): absolute neutrophil count (ANC) >= 1500 cells/u
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Neutrophil count of > 1500/mm^3
+Absolute neutrophil count >= 1,500 cells/mm^3 based on complete blood count (CBC)/differential within 14 days prior to Step 2 registration
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L in absence of growth factor support
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (> 1500 per mm^3)
+Within 14 days of the first study treatment: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) ?1500/millimeters cubed (mm^3) (?1.5 × 10^3/microliters [µL])
+Within 14 days prior to registration: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500 per mm^3)
+Absolute neutrophil count (ANC) < 1500 cells/mm^3 at the time of screening
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (> 1500 per mm^3)
+Absolute neutrophil count (ANC) >= 1,000/ L
+Within 14 days prior to cycle 1 day 1 of treatment: Absolute neutrophil count (ANC) >= 1,000 K/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >=1.5 x 10^9/L (>= 1500 per mm^3)
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count of >= 1,500
+Absolute neutrophil count greater than 1500/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500 per mm^3)
+absolute neutrophil count (ANC) ? 1.5 x 109/L;
+Absolute neutrophil count (ANC) < 1,000/mm3 without growth factor support within 7 days prior to testing
+Absolute neutrophil count >= 1,500
+(For both cohorts A and B): Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1500/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
+Absolute neutrophil count (ANC) >= 1.5 x 10^9 cells/mL
+Absolute neutrophil count (ANC) ? 1,500 cells/mm3cells
+Absolute lymphocyte count (ALC) >1000 cells/mm3
+Within 4 weeks prior to the registration: absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Peripheral absolute neutrophil count (ANC) >= 1,000/mm^3
+Participants with an absolute neutrophil count (ANC) >= 1000/mm^3, within 21 days of initiation of protocol therapy; growth factor within 7 days of screening is not allowed to meet ANC eligibility criteria
+Participants with an absolute neutrophil count (ANC) < 1000/mm^3, within 21 days of initiation of protocol therapy; growth factor within 7 days of screening is not allowed to meet ANC eligibility criteria
+Platelets > 100,000 cells/mm3 and absolute neutrophil count (ANC) > 1,250 cells/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^ 9/L
+Absolute neutrophil count (ANC) >= 1500/mm^3 (1.5 x 10^9/L)
+Peripheral absolute neutrophil count (ANC) >= 1000/mm^3 within 14 days of registration
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500 per mm^3)
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Within 28 days prior to registration for protocol therapy: Absolute neutrophil count (ANC) >= 1,500 K/mm^3
+Absolute neutrophil count >= 1.0 x 10^9/L
+Neutrophil >1500/mm3
+Absolute neutrophil count >= 1,500/mm^3 OR >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1500/mm^3 obtained =< 7 days prior to registration
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,000
+Absolute neutrophil count (ANC) >= 1,000/mm^3 without transfusion or growth factor support for at least 1 week
+Determined within 3 weeks of treatment initiation: Absolute neutrophil count >= 1,000/mm^3 (1.0 x 10^9/L)
+Absolute neutrophil count >= 1500/mL.
+Peripheral absolute neutrophil count (ANC) ? 1000/mm^3
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L, measured within 28 days prior to administration of study treatment
+Absolute neutrophil count >= 2000 cells/mm^3
+Absolute neutrophil count (ANC) < 1500/mm^3
+Subjects with an absolute neutrophil count (ANC) of equal to or higher than 0.5 x 10^9 at the screening visit
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1000/mm^3 obtained =< 14 days prior to registration
+Absolute neutrophil count (ANC) >= 1500 cells/ml
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (> 1500 per mm^3).
+Absolute neutrophil count (ANC) >= 1.5 X 10^9/L
+Performed within 14 days (+ 3 working days) prior to registration: Absolute neutrophil count (ANC) > 1,500/mm^3.
+Absolute neutrophil count (ANC) >= 1000/mm^3 (obtained =< 14 days prior to registration)
+Absolute neutrophil count (ANC) >= 1500 mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count >=1000/mm^3 [1.0 x 10^9/ liter (L)]
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count levels < 0.5 × 10^9/L in the 4 weeks before screening
+Absolute neutrophil count (ANC) ? 1.5 x 10 9/L
+Absolute neutrophil count >= 1500 per microliter
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500 per mm^3) within 28 days prior to study registration
+Absolute neutrophil count (ANC) > 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1 x 10^9/L
+Obtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1,000 cell/mm^3 without growth factor support
+To be performed within 10 business days prior to day 1: Absolute neutrophil count (ANC) >= 1,000/mm^3; filgrastim can be given prior to enrollment to achieve target ANC >= 1000/uL
+Absolute neutrophil count (ANC) >= 1500/mm^3, obtained =< 14 days prior to registration
+Obtained =< 7 days prior to registration: Absolute neutrophil count (ANC) >= 1500/mm^3
+Within 14 days prior to planned start of treatment: Absolute neutrophil count (ANC) >= 1000/mm^3\r\n* Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement
+Absolute neutrophil count (ANC) >= 1000/mm^3, unless due to disease involvement in the bone marrow
+Absolute neutrophil count (ANC) >= 1.5 K/cu mm
+Absolute neutrophil count (ANC) >= 1500/mm^3 obtained =< 14 days prior to registration
+Absolute neutrophil count (ANC) > 1000/mm^3
+Absolute neutrophil count (ANC) > 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500 per mm^3)
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count < 500 at the time of enrollment
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) > 1,500 cell/mm3.
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Neutrophil count >= 1000 prior to biopsy
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) count >= 1.5 X 10^9/L
+Absolute neutrophil count (ANC) >= 1500/mm^3; (ANC > 1000/mm^3 may be considered in special circumstances such as benign cyclical neutropenia as judged by the investigator and in discussion with the sponsor)
+Patients must have an absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Aplastic anemia with absolute neutrophil count (ANC) < 1,000 and transfusion dependent after failed immunosuppression therapy
+Absolute neutrophil count (ANC) >= 1.0 x 10^9 /L
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500 per mm^3)
+Absolute neutrophil count <1.5 x 10^9/L (<1500/mm3)
+Absolute neutrophil count (ANC) >= 1.5 X 10^9/L, within 14 days start of study start
+Absolute neutrophil (ANC) >= 1,500/mm^3 (>= 1.5 X 10^6/L)
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count > 750 cells/mm^3 (1.0 x 10^9/L)
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count ? 1.5 × 10^9/L
+Absolute neutrophil count >= 1000 cells/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count < 1.0 x 10^9 /L
+Absolute neutrophil count (ANC) >= 1000/mm^3 independent of growth factor support
+Absolute neutrophil count > 1800 cells/cubic mm
+Absolute neutrophil count (ANC) > 1,500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3
+Absolute neutrophil count (ANC) < 1000/mm^3 unless lymphoma, KSHV-MCD, or KICS-related
+Absolute neutrophil count (ANC) < 1.5 x 10^9/L (1500 per mm^3)
+Obtained within 14 days prior to registration; absolute neutrophil count (ANC) ?1,500 cells/mm^3
+Absolute neutrophil count (ANC) < 1500/mL
+Absolute neutrophil count (ANC) >= 1.5 cells/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500 per mm^3)
+Within 60 days prior to registration, hematologic minimal values: absolute neutrophil count > 1,500/mm^3
+Absolute neutrophil count > 750 cells/mm^3 (0.75 x 10^9/L)
+Absolute neutrophil count >= 1,500/mL
+Absolute neutrophil count (ANC) < 500/ml
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count >= 1.5 x 10^9 cells/L
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (> 1500 per mm^3)
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L\r\n* By automated or manual review, whichever is greatest
+Absolute neutrophil count >= 1,000/dL
+Obtained =< 14 days prior to randomization: Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count [ANC] < 1500/mm^3
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) ? 1.5 K/mm^3 (must be stable off any growth factor within 4 weeks of first study drug administration)
+Absolute neutrophil count =< 1.5 x 10^9/L
+Completed within 60 days of surgery: Absolute neutrophil count (ANC) ? 1500/mm^3
+Absolute neutrophil count (ANC) >= 1000 (within 14 days prior to registration)
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count ? 1500/?L
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count >= 1.5 x 10^9/L (1,500/mm^3)
+Absolute neutrophil count >= 1,000/mm^3
+Neutrophil count of >= 1.0x 10^9 cells/L
+Neutrophil count of >= 1.0 x 10^9 cells/L
+Absolute neutrophil count (ANC) >= 0.5 x 10^9/L without daily use of myeloid growth factor
+Neutrophil count of >= 1.5 x 10^9 cells/L
+Absolute neutrophil count (ANC) < 1,000/mm^3 (Unit of International System of Units [SI] units 109/L)
+PART 2 GROUP 1 INCLUSION CRITERIA: Peripheral absolute neutrophil count (ANC) >= 1000/mm^3 (1.0 x 10^9/L) without granulocyte growth factor for >= 7 days
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count >= 1.5 x 10^9 cells/L
+Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) < 1000/mm^3
+Absolute neutrophil count (ANC) >= 1800/mm^3
+Absolute neutrophil count (ANC) > 1.5 X K/mm^3
+Absolute neutrophil count (ANC) ? 1.5 x 109/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9 cell/ml
+Absolute neutrophil count < 1 x 10^9/L
+Absolute neutrophil count >= 1000 cells/mm^3, with or without transfusion support; NOTE: If the patient’s bone marrow biopsy shows greater than or equal to 50% plasma cells, absolute neutrophil count (ANC) > 500 cells/mm^3 (transfusion support or growth factor support is acceptable)
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute neutrophil count (ANC) >= 1.0 K/cu mm; for subjects with ANC < 1.0 K/cu mm due to significant marrow involvement by MCL, ANC must be > .5 K/cu mm
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (> 1500 per mm^3)
+Absolute neutrophil count (ANC) >= 1 x 10^9/L
+Absolute neutrophil count >= 1000/mm^3
+Absolute neutrophil count (ANC) < 1500/mm^3
+Absolute neutrophil count (ANC) < 1,000/mm^3 [1.0 x 10^9/L]
+EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Absolute neutrophil count (ANC) < 1000/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) ?1.0 x 109/l, hemoglobin ?8 g/dl, platelet count ? 100 x 10^9/l, prothrombin (INR) <1.5.
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500 per mm^3)
+Obtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1500
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1500
+Absolute neutrophil count (ANC) ? 1,000/mm^3 (1.0 x 10^9/L);
+PRIOR TO LYMPHODEPLETION: Absolute neutrophil count (ANC) is > 1,000 cells/mm^3
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1500/mL
+Absolute neutrophil count >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute lymphocyte count (ALC) >= 500/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) ? 1.0 x 109 cells/L
+Absolute neutrophil count ?1.5 x 109/L;
+Absolute neutrophil count (ANC) < 1,000/mm^3 (1.0 x 10^9/L)
+Hemoglobin ? 9.0 g/dl, absolute neutrophil count (ANC) ? 1,500 cells/µl, platelets ? 125,000 cells/µl
+Absolute neutrophil count (ANC) ? 1500/L
+Obtained =< 14 days prior to registration: Absolute neutrophil count >= 1000/mm^3
+Absolute neutrophil count >= 1,500 cells/mm^3
+absolute neutrophil count ? 1.5x10^9/L
+Absolute neutrophil count (ANC) > 1,500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count > 500 mL
+Absolute neutrophil count (ANC) >= 1,200/mm^3
+Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1,000/mm^3 without growth factor use =< 7 days prior to C1D1
+Recovery from last induction course of chemotherapy (absolute neutrophil count [ANC] > 500 and platelet > 20,000)
+Absolute neutrophil count (ANC) ? 1.5 x109/L.
+Leukocytes absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count >= 1.5 x 10^9 cells/L
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) ? 1.5 x 10^9/L (? 1500 per mm^3)
+CAPMATINIB INCLUSION CRITERIA: Absolute neutrophil count >= 1,500/mm^3
+REGORAFENIB INCLUSION CRITERIA: Absolute neutrophil count >= 1,500/mm^3
+ENTRECTINIB INCLUSION CRITERIA: Absolute neutrophil count >= 1,000/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3
+No significant anemia (hemoglobin below 9.0 g/dL) or neutropenia (absolute neutrophil count [ANC] < 1000/mm^3)
+Absolute neutrophil count (ANC) >= 1,000 cells/mm^3 without growth factors within 1 week of the initiation of treatment
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Within 14 days prior to registration: Absolute neutrophil count >= 1.5 x 10^9 cells/L
+Absolute neutrophil count (ANC) of < 1.5×109/L, or platelet count of < 100 ×109/L, or hemoglobin < 9g/dL;
+Absolute neutrophil count >= 1000/?l
+Absolute neutrophil count (ANC) ? 1500/?l
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
+Absolute neutrophil count greater than or equal to 1500/mm^3
+Absolute neutrophil count (ANC) >= 1 x 10^9 (International System [SI] units 10^9/L) (with or without filgrastim [G-CSF])
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 K/CUMM
+Absolute neutrophil count (ANC) >= 1,000/mL
+Absolute neutrophil count (ANC) >= 1500/mm^3, obtained =< 7 days prior to registration
+Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute neutrophil count (ANC) > 1,000/mm^3
+Absolute neutrophil count (ANC) >= 1.2 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute neutrophil count (ANC) ? 1,000/µL
+Absolute lymphocyte count ? 100/µL
+Absolute neutrophil count (ANC) >= 1000/mm^3; growth factor is not permitted within 14 days of neutrophil assessment
+Absolute neutrophil count >= 1.5 × 10^9/L
+Within 6 weeks of day 1: Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count >= 1,500/mm3
+Absolute neutrophil count (ANC) >= 1000/mm^3 or >= 750/mm^3 in the setting of marrow involvement by disease (independent of growth factor or transfusion support)
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (measured within 28 days prior to administration of study treatment)
+Absolute neutrophil count (ANC) >= 1,500/mm^3 (1.5 x 10^9/L)
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Peripheral blood (PB) showing at least two of the following criteria: Absolute neutrophil count (ANC) < 0.5 k/µL Platelet count < 30 k/µL Absolute reticulocyte count < 60,000/µL
+Absolute neutrophil count > 100 cells/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) ? 1.5 x 10^9 cells/L
+Absolute neutrophil count (ANC) < 1500 per mm^3
+Absolute neutrophil count (ANC) < 1,000/mm^3
+Absolute lymphocyte count < 200/ mm^3
+Absolute neutrophil count >= 1500/mm^3
+ADDITIONAL CRITERIA FOR STUDY CONTINUATION: Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1500/?L
+Absolute neutrophil count >= 1.5 K/cu mm
+An absolute neutrophil count (ANC) > 1,000/mm^3 (patients who have bone marrow infiltration by MCL are eligible if their ANC is >= 500/mm^3 [growth factor allowed]; these patients should be discussed with either the principal investigator [PI] or Co-PI of the study for final approval)
+Absolute neutrophil count (ANC) ? 1000/mm3, independent of growth factor support;
+Neutrophil count >= 1000/mm^3 (no growth factors within 5 days)
+Absolute neutrophil count of < 1.0 x 10^9/L
+Peripheral absolute neutrophil count (ANC) greater than or equal to 1000/microL
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) > 1500/l
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Peripheral absolute neutrophil count (ANC) >= 1,000/mm^3
+For subjects with solid tumors without known bone marrow involvement: peripheral absolute neutrophil count (ANC) >= 750/mm^3
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
+Absolute neutrophil count (ANC) greater than or equal to 1000/mm^3
+Absolute neutrophil count (ANC) ? 1,000/mm^3
+Absolute neutrophil count (ANC) < 1.5 x 10^9/L
+Absolute neutrophil count (ANC) 550/cu mm (off myeloid growth factors)
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) > 1.5 x10^9/L
+Peripheral absolute neutrophil count (ANC) ? 1000/mm³.
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1500 cells per mm^3
+Absolute neutrophil count (ANC) >= 1,000/mm^3 without growth factor support
+Absolute neutrophil count >= 750/mm^3
+Absolute Neutrophil Count (ANC) <1.5 x 109/L
+Absolute neutrophil count (ANC) >= 1,500/microliter
+Absolute neutrophil count (ANC) >= 1500/mm^3
+The absolute neutrophil count (ANC) count >= 1500
+Absolute neutrophil count > 1000/mm^3
+Absolute neutrophil count >= 1.0 x 10^9 cells/L (growth factor use is allowed)
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1500
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3 prior to biopsy
+TREATMENT: Engrafted post-transplant (absolute neutrophil count [ANC] > 500 for at least 3 consecutive days) and ANC > 500 at the time of infusion
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1000/ucl obtained within 28 days prior to registration
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Hematology: . Absolute neutrophil count ? 1.5 x 109/L or ? 1,500/µl Platelets ? 100 x 109/L or ? 100,000/µl
+Absolute neutrophil count >= 1.5 x 10^9/L, obtained within 30 days of study registration
+Absolute neutrophil count (ANC) >= 1000/mm^3
+absolute neutrophil count (ANC) must be greater than or equal to 1000/mm3;
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3 or >= 1.5 bil/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 (system international [SI] units 1.5 x 10^9/L)
+Absolute neutrophil count >= 1,500/mm^3
+Evidence of neutrophil engraftment defined as the absolute neutrophil count (ANC) > 0.5 x 10^3/for 3 consecutive days
+Absolute neutrophil count (ANC) > 1,000
+Absolute neutrophil count of >= 1500/mm^3
+Absolute neutrophil count =< 1500 per mm^3
+Absolute neutrophil count (ANC) >= 1000/mm^3 or >= 750/mm^3 in the setting of marrow involvement by disease
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Within 2 weeks of enrollment: Absolute neutrophil count, >= 1500 cells/mm^3
+Absolute neutrophil count (ANC) > 1500/mm^3
+absolute neutrophil count ? 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) > 0.75
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) ? 1.5 × 109/L
+Absolute neutrophil count (ANC) > 0.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) > 1.5 x 10^9/L
+Absolute neutrophil count < 1500/mm3
+Absolute neutrophil count (ANC) < 1500/mm^3
+Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) >= 0.5 x 10^9/L (1500/mm^3)
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3 (1.5 × 10^9/L)
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+b. Absolute neutrophil count (ANC) ? 1,500/µL
+Absolute neutrophil count (ANC) > 1500/mm^3
+Absolute neutrophil count of >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.0 × 10^9/L
+Absolute neutrophil count (ANC) is >= 1,000
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L; ANC < 1.5 x 10^9/L if cytopenia is due to extensive bone marrow involvement of disease as determined by the treating physician
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 × 10^9/L
+Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L within 14 days prior to starting therapy
+Absolute neutrophil count (ANC) < 1500/mm3
+Absolute neutrophil count >= 1000/mm^3
+Within 14 days prior to registration: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count >= 1,500/µL
+Neutrophil count of > 1500/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count >= 1500 per mm^3 AND
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) > 500
+Absolute neutrophil count (ANC) >= 750 X 10^9 /L without transfusion if stem cells are not available
+Absolute neutrophil count (ANC) >= 1,800 cells/mm^3
+Absolute neutrophil count (ANC) >= 1,800 cells/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) > 1500, unless due to direct bone marrow involvement of disease
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3 or >= 1.5 bil/L
+Absolute neutrophil count (ANC) ? 1500/mm3
+Absolute neutrophil count >= 1.5 x 10^9 cells/L
+Absolute neutrophil count of >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Peripheral absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count >= 1,000/mm^3, within 14 days prior to study entry
+Absolute neutrophil count more or equal to 750/mL
+Absolute neutrophil count >= 1,000/mL
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,000/mL
+Absolute neutrophil count >= 1000/mL
+Absolute neutrophil count (ANC) >= 1000 cells/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Patients should have an absolute neutrophil count (ANC) of > 500?L
+Absolute neutrophil count (ANC) >= 1000/mm^3; this value must be obtained within four weeks before protocol entry
+Absolute neutrophil count (ANC) >= 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) >= 1.5 X 10^9/L (performed within 14 days prior to registration)
+Absolute neutrophil count (ANC) >=1,500/mm^3
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
+Absolute neutrophil count >= 1.0 x 10^9/L
+Absolute neutrophil count >= 1,500/mL
+Absolute neutrophil count < 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1500/mm^3 obtained =< 14 days prior to registration
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) < 1.0 x 10^9/L
+Absolute lymphocyte count < 0.5 x 10^9/L
+Obtained =< 28 days prior to randomization:\r\nAbsolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count >= 750 cells/mm^3 (0.75 x 10^9/L), at screening
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3
+Absolute neutrophil count >= 1,000 microliter
+Absolute peripheral neutrophil count (ANC) of >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute neutrophil count (ANC) < 1500/mm3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,800 cells/mm^3
+Absolute neutrophil count >= 0.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1500
+Absolute neutrophil count (ANC) greater than or equal to 750/mm^3
+Absolute neutrophil count (ANC) > 500
+Absolute neutrophil count (ANC) >= 1500/cu mm
+Absolute lymphocyte count >= 500/cu mm
+Absolute neutrophil count (ANC) > 1,500/mm^3
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) < 1500/mm^3
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count (ANC) > 1000
+Absolute neutrophil count (ANC) > 1000
+In patients < 18 years of age, moderately severe aplastic anemia is defined as having at least one of the following:\r\n* Platelet count < 40 x 10^9/L\r\n* Absolute neutrophil count (ANC) < 10 x 10^8/L\r\n* Hemoglobin (Hgb) < 9 g/dL
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count < 1,500 cells/mm3.
+Absolute neutrophil count (ANC) ? 1.5 x 109/L
+Neutrophil count of > 1,500/mL
+Anticancer agents not known to be myelosuppressive (eg, not associated with reduced platelet or absolute neutrophil count [ANC] counts): ?7 days after the last dose of agent.
+Absolute neutrophil count (ANC) ?1000/mm3.
+Absolute neutrophil count (ANC) >= 1000/mm^3 obtained =< 14 days prior to registration
+Absolute neutrophil count (ANC) >= 1500/mm^3, obtained =< 14 days prior to registration
+Absolute neutrophil count ? 1,500/µL
+absolute neutrophil count ? 1000/?L,
+Absolute neutrophil count (ANC) <1000/mm3
+Absolute neutrophil count (ANC) >= 1.5 K/mm^3
+Absolute neutrophil counts ? 1500 cells/ mm3
+Absolute neutrophil count (ANC) >= 1,500/mm^3 (repeat if more than 3 days before the first dose)
+Absolute neutrophil count (ANC) <1.5 X 109/L
+Absolute neutrophil count (ANC) < 1.5 x 109/L
+Absolute neutrophil count ? 1500/?L
+Absolute neutrophil count (ANC) ?750 cells/mm3 (1.0 x 109/L)
+Absolute neutrophil count (ANC)>1500/mm3
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L; screening ANC should be independent of growth factor support for over one week for all patients
+Absolute neutrophil count (ANC) >= 1500
+Absolute neutrophil count (ANC) ? 1.5 x 109/L
+Absolute neutrophil count (ANC) >= 1.5K/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 100/L
+Neutrophil count >= 1.5 x 10^9/l
+Absolute neutrophil count >1000/mm3
+Absolute lymphocyte count (ALC) >= 500/mm^3
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute neutrophil count (ANC) ?1,500/mm3
+Absolute neutrophil count (ANC) ? 1500/mm^3
+Within 14 days prior to randomization: Absolute neutrophil count (ANC) must be >= 1200/mm^3
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L within 28 days prior to administration of study treatment.
+Adequate neutrophils (defined as absolute neutrophil count >= 1,500/mm^3).
+Within 28 days prior to administration of study treatment: Absolute neutrophil count (ANC) ? 1.5 x 10^9/L
+Absolute neutrophil count (ANC) ? 1,000/mm^3
+Absolute neutrophil count ?1500 cells/mm3
+Within 14 days of first dose of study drug: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) ? 1.0 x 109 cells/L
+Absolute neutrophil count (ANC) ? 1500 /µL
+Absolute neutrophil count >= 1,500/microliter
+Absolute neutrophil count (ANC) > 1500, unless due to direct bone marrow involvement of disease
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count greater than 1000 /mm³
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
+Within 14 days of study drug(s) initiation: Absolute neutrophil count (ANC) >=1500/·L.
+Absolute neutrophil count (ANC) ? 1.5x10^9/L for paclitaxel cohort, and ? 1.0x10^9/L for endocrine therapy cohort
+Absolute neutrophil count >= 1500/mL
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3 within 28 days prior to registration.
+Absolute neutrophil count >= 1500/mL
+For subjects with solid tumors without known bone marrow involvement: \r\n*Peripheral absolute neutrophil count (ANC) ? 750/mm^3
+Obtained ? 14 days prior to registration: absolute neutrophil count (ANC) ? 1000/mm^3
+Absolute neutrophil count (ANC) ? 1500/microliter
+Neutrophil count >= 1.5 x 10^9/L
+Within 14 days prior to first dose of study drug treatment: Absolute neutrophil count (ANC) >= 1.5 x 109/L
+Absolute neutrophil count greater than 1000/mm3 without the support of filgrastim
+Absolute neutrophil count >= 1.5 × 10^9/L =< 14 days prior to registration
+Absolute neutrophil count =< 1500/mm^3.
+Absolute neutrophil count (ANC) ? 1500/mm^3
+Absolute neutrophil count >= 1,000/mm^3, within 28 days of day 0.
+Within 10 days of treatment initiation: Absolute neutrophil count (ANC) >= 1.5 x 109/L
+Within 14 days of study registration: Absolute lymphocyte count: >= 500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) ? 1500 cells/mm^3 ? 2 weeks
+Absolute neutrophil count (ANC) >= 1 K/cu mm
+Absolute neutrophil count >= 1,500
+Obtained =< 21 days prior to registration: Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3 (without transfusion or growth factor support)
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L (>=1000 per mm^3).
+Absolute neutrophil count >= 1.5 x 10^9/L
+Obtained within 28 days prior to registration: Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (> 1500 per mm^3) except for patients with HCC for whom ANC >= 1000 per mm^3 is allowed
+Absolute neutrophil count (ANC) >= 1000/mm^3 without transfusion support.
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+ANC (absolute neutrophil count) is 1,500
+Blood counts performed within 3 weeks prior to starting study therapy must have absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/ L
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (> 1500 per mm^3)
+Absolute neutrophil count (ANC) less than or equal to 1000
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1500/µL
+Absolute neutrophil count (ANC) >= 1.5 K/mm^3
+Absolute lymphocyte count >= 500/mm^3
+Absolute neutrophil count >= 1,500 per mm^3
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3
+Absolute Neutrophil Count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,500/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
+Absolute neutrophil count > 1,000/mm^3
+Absolute lymphocyte count > 1,000/mm^3
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute Neutrophil Count (ANC) > 1000/mm3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute Neutrophil Count (ANC) >= 1.0 x 10^9 cells/ L
+To be performed within 28 days prior to day 1 of protocol therapy: Absolute neutrophil count (ANC) >= 1500/mm^3\r\n* NOTE: Growth factor is not permitted within 14 days of ANC assessment unless cytopenia is secondary to disease involvement
+Absolute neutrophil count (ANC) >= 1,000 cells/mm^3
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count <1.0 × 10^9/L.
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Within 14 days prior to registration: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.2 x 10^9/L
+Within 7 days prior to study registration: Peripheral absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3 (1.50 x 10^9 /L) obtained =< 28 days prior to registration
+Absolute neutrophil count (ANC) >= 1000/ millimeter cube (mm^3) (1.0 x 109^9/liter [L])
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count >= 1,500/mm^3
+Within 28 days of study registration: Absolute neutrophil counts >= 1500 cell/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3, unless secondary to bone marrow involvement; obtained =< 7 days prior to registration
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) must be >= 1200/mm^3 within 28 days before randomization
+Absolute neutrophil count >= 1.5 x 10^9/L
+Within 14 days prior to step 1 registration: Absolute neutrophil count (ANC) >= 1,000 cells/mm^3
+Performed within 14 days prior to study: Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count (ANC) < 1,000/mm^3
+Absolute neutrophil count (ANC) >= 1200/mm^3
+Absolute neutrophil count (ANC): >= 1,500 /mm^3
+Absolute neutrophil count >= 1500 cells/mm^3, obtained within 14 days prior to registration for protocol therapy
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) ?1.0 x 109 /L, hemoglobin ?8 g/dL, and platelet count ? 75 x 109/L.
+Absolute lymphocyte count >= 500/mm^3
+Absolute neutrophil count (ANC) >= 1500
+ARM A: obtained =< 14 days prior to registration: \r\n* Absolute neutrophil count (ANC) >= 1000/mm^3
+ARM B: obtained =< 14 days prior to registration: \r\n* Absolute neutrophil count (ANC) >= 1000/mm^3
+Measured within 28 days prior to administration of study treatment: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1500/mm^3 or >= 1.5 x 10^9/L, obtained =< 14 days prior to registration
+Obtained within 30 days prior to registration: Absolute neutrophil count (ANC) >= 1.5 K/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500 per mm^3)
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Peripheral absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Obtained =< 7 days prior to registration: Absolute neutrophil count (ANC) >= 1700/mm^3
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1500 cells per mm^3
+Absolute neutrophil count (ANC) >= 1.2 x 10^9/L
+Absolute Neutrophil Count (ANC) < 1,500/µL
+Absolute neutrophil count (ANC) >= 1000 x 10^9/L, unsupported by filgrastim (G-CSF) or granulocytes
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) > 1000/mm^3
+Patients must have adequate hematologic reserve as evidenced by absolute neutrophil count (ANC) >= 1500/mm^3 and platelets >= 100,000/mm^3
+Absolute neutrophil count (ANC) > 1,500/mm^3
+Absolute neutrophil count: >= 750/mm^3
+Absolute Neutrophil Count (ANC) >= 1500 per mm^3
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L within 2 weeks before baseline
+Absolute neutrophil count greater than 1500/mm^3
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute neutrophil count of > 1500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count less than 500/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3 (obtained =< 14 days prior to registration)
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3 or >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) > 1000/mm^3
+Absolute neutrophil count (ANC) >= 1,800 cells/mm^3
+Absolute neutrophil count >= 1000/mm^3
+Absolute neutrophil count >= 1.5 × 10^9/L
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count >= 1.5 × 10^9/L
+Absolute neutrophil count (ANC) > 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) > 1500
+Absolute neutrophil count (ANC) > 1500/mm^3
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3, within 14 days prior to registration
+Absolute neutrophil count >= 1,000/mm^3
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Peripheral absolute neutrophil count (ANC) >= 1000/mm^3
+For patients with solid tumors without bone marrow involvement: peripheral absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L without growth factor support
+For patients with solid tumors without known bone marrow involvement: peripheral absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) must be > 750/mm^3 (not achieved by transfusion)
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) must be >= 1200/mm^3
+Absolute neutrophil count (ANC) < 1000 / mm^3
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.2 x 10^9/L, within 2 weeks of the first dose of study treatment
+Absolute neutrophil count (ANC) >= 1.2 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1,000 cell/mm^3 without growth factor support within 14 days prior to registration
+Absolute neutrophil count (ANC) >= 1000
+Absolute neutrophil count greater than 1500/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) >= 500
+Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) ? 1.0 × 109/L within 14 days prior to randomization
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L, measured within 28 days prior to administration of study treatment
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count >= 1,500/mm^3
+PHASE II: Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count of >= 1,500 or cells/mm^3
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute-neutrophil count (ANC ) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) < 1.5
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) must be > 750/mm^3 (unless due to underlying disease in which case there is no grade restriction)
+Absolute neutrophil count >= 1,000/mm^3
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Granulocytes/absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute CD4 count of < 50 cells/ mm^3
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3
+Absolute neutrophil count >= 1500/mL
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 for 5 days after recovery from ASCT nadir
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) > 500
+Participants with an absolute neutrophil count (ANC) < 1000/mm^3, within 21 days of initiation of protocol therapy; growth factor within 7 days of screening is not allowed to meet ANC eligibility criteria
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/l
+Neutrophil count < 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,500/mm^3 within four weeks prior to randomization
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count ?1500/mm3;
+Absolute neutrophil count (ANC) < 1,000 cells/mm^3 within 21 days of initiation of protocol therapy; growth factor administration is not allowed to meet ANC eligibility criteria
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Platelet count < 50 x10^9/L or absolute neutrophil count (ANC) < 1 x10^9/L at the Screening visit
+Absolute neutrophil count (ANC) greater than 500/µL.
+Absolute neutrophil count (ANC) > 1.000/mm3
+Absolute lymphocyte count (ALC) ? 300/mm3
+Absolute neutrophil count (ANC) ? 1.5 x 109/L,
+Absolute neutrophil count (ANC) >1500 cells/mm3
+Absolute neutrophil count (ANC):
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count >= 1,500 mm^3
+Absolute neutrophil count ? 1000/µL
+Must have neutrophil count >1200/mm3 (1.2x109/L)
+Absolute neutrophil count >= 1500 cells/mm^3
+Absolute neutrophil count ?1000 cells/mm3
+Neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) < 1,000/?L
+Absolute neutrophil count (ANC) ? 1.5 x 10^9/liter (L) and
+Absolute neutrophil count (ANC) ? 1,500 cells/mm3
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) greater than or equal to 1,500/mcL (ANC >= 1.5 x 10^9/liter [L])
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Neutropenia (absolute neutrophil count < 1500 cells/µL)
+absolute neutrophil count >750/µL
+Absolute neutrophil count (ANC) >= 1000/mm^3, obtained =< 21 days prior to registration
+Absolute neutrophil count ? 1.0 X 10 9/L,
+MF PATIENTS: Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1500
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute neutrophil count (ANC) < 1000
+Absolute neutrophil count ? 1000 /mm^3
+Adequate bone marrow function as assessed by absolute neutrophil count (ANC) ? 1500/mm3; hemoglobin ? 9.0 g/dL, and platelet count ? 100,000/mm3.
+Absolute neutrophil count (ANC) ?1000/?L.
+Absolute neutrophil count (ANC) must be greater than or equal to 1500/mm3;
+SUB-PROTOCOL AIM A: Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) > 1,500 cells/mm^3
+Absolute Neutrophil count (ANC) ?1.0 x10?/L (without G-CSF support)
+Absolute neutrophil count ?1500 cells/ml,
+Absolute neutrophil count ? 1.5 x 10^9/L
+absolute neutrophil count ?1.5 × 109/L
+Absolute neutrophil count (ANC) at least 1,500/mm3
+Absolute neutrophil count ? 1500 cells/mm3
+Absolute neutrophil count ? 1.5 x 10^9/L
+Bone marrow reserve: Absolute neutrophil count (ANC) ? 1.5 x 109/L. Platelets ? 100 x 109/L. Hemoglobin ? 9 g/dL.
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3 within 14 days prior to study registration
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
+Absolute neutrophil count (ANC) >= 1.2 x 10^9/L without growth factor support
+Absolute neutrophil count ? 1,000 cells/dL (1.0 x 109/L)
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute neutrophil count (ANC) ? 1,500 cells/mm3
+Within 14 days prior to registration: Absolute neutrophil count (ANC) >= 1,000 cells/mm^3 without growth factor support
+Absolute neutrophil count >= 1500/mm^3
+Absolute Neutrophil Count (ANC) ? 1.5 x 109/L without growth factor support for 7 days (14 days if received pegfilgrastim).
+Absolute neutrophil count >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1,500/ mm^3
+Absolute neutrophil count (ANC) > 1.0 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count ? 1500/mm3
+Absolute neutrophil count ? 1000mm3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/l
+Absolute neutrophil count ? 1.5 x 10^9/L
+Absolute neutrophil count >= 1000/mm^3
+Absolute neutrophil count (ANC) ?1.5 x 109/L
+Absolute Neutrophil Count (ANC) < 1.5x109/L
+Platelet count ? 100,000 /mm3, hemoglobin (Hb) ? 9 g/dL, absolute neutrophil count (ANC) ? 1500/mm3. Blood transfusion to meet the inclusion criteria will not be allowed.
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) ?1,500 /mL
+Within 14 days of study start: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute lymphocyte count ? 800/?L before the first dose of CG0070
+Absolute Neutrophil Count (ANC) <1.5 x 109/L (1.5x103/µL)
+Absolute neutrophil count >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) > 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
+Absolute neutrophil count > 500/mm3
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute neutrophil count (ANC) < 1500/ml, and/or
+Absolute neutrophil count (ANC) >= 500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9
+Neutrophil count ? 1,500/mm3
+Hematologic: Absolute neutrophil count (ANC) 1.5 x 109/liter (L), platelets 100 x 109/L, and hemoglobin 8 gram/deciliter (g/dL).
+Absolute neutrophil count >= 1.5 x 10^9 cells/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute neutrophil count > 1,500/mm^3
+Absolute neutrophil count (ANC) ? 0.75 x 10^9/L in the absence of growth factor in the prior 7 days
+Absolute neutrophil count (ANC) >= 1500 cells per mm^3
+Absolute neutrophil count less than 1000/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9 (SI units 10^9/L)
+Absolute neutrophil count (ANC) greater than or equal to 1.5 X 10^9/L
+Absolute neutrophil count >= 1,500/L
+Absolute neutrophil count > 1,500/mm^3
+Absolute neutrophil count >= 1.0 x 10^ 9/L
+Absolute neutrophil count >= 1,300/microliter
+Absolute neutrophil count (ANC) >= 1,500/mm^3 (1.5 x 10^9/L) (unless due to marrow involvement) obtained within 4 weeks prior to registration
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1,800 cells/mm^3
+Absolute neutrophil count (ANC) >= 1,800 cells/mm^3
+Absolute neutrophil count >= 1.5 x 10^9 cells/L
+Absolute neutrophil count (ANC) >= 1,000/ mm^3
+Absolute neutrophil count (ANC) >= 1000
+Absolute neutrophil count (ANC) >= 1000/mm^3 obtained =< 7 days prior to registration
+Within 14 days of enrollment: Absolute neutrophil count >= 1500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1.0/mm^3, ANC >= 0.5/mm^3 (if patient has baseline neutropenia due to lymphoma)
+Absolute neutrophil count (ANC) >= 1500/mm^3 (within 14 days prior to day 1 of protocol therapy)
+Absolute Neutrophil Count* ? 1,500/mm3 (? 1.5 x 109/L)
+Absolute neutrophil count (ANC) ?1.5×109/L
+Absolute neutrophil count (ANC) ? 1.5 × 10e3/µL
+Absolute neutrophil count ? 1.5 x 106/µl
+Absolute neutrophil count (ANC) ? 1.5 x 10^9/L (1500/mm3)
+Absolute neutrophil count < 1.0 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) must be > 1.0 x 10^9/L
+Absolute neutrophil count (ANC) >= 1 x 10^9/L
+Absolute neutrophil count >= 1,500 cells/mm^3
+Absolute neutrophil count > 1000/?L
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) ?1500/?L.
+Prior to cyclophosphamide and T cell infusions: absolute neutrophil count (ANC) =< 1000
+Absolute neutrophil count >= 1.5 x 109/L.
+Absolute neutrophil count >= 1.0 x 10^9/L
+Absolute neutrophil count (ANC) > 1500
+Absolute neutrophil count (ANC) < 1500/ml
+Absolute neutrophil count (ANC) >= 1500/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
+Absolute neutrophil count (ANC) >= 1.5 X 10^9/L (> 1500 per mm^3), obtained within 14 days prior to first treatment
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1400/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.0 x 10^9 /L
+Absolute neutrophil count (ANC) >= 1,500
+Absolute neutrophil count >= 1,000/mm^3
+Absolute neutrophil count ? 1.5 x 10^9 cells/L
+Marrow: Hemoglobin >= 10.0 g/dL, absolute neutrophil count (ANC) >=1,500/mm3, and platelets >=100,000/mm3.
+Within 28 days prior to signing informed consent: Absolute neutrophil count (ANC) >= 1,000/mm^3, independent of growth factor support
+Absolute neutrophil count (ANC) > 1.5 x 10^9/L (within 7 days prior to registration)
+Absolute neutrophil count (ANC) >= 1000
+Absolute neutrophil count (ANC) > 1,000/mm^3
+Absolute neutrophil count (ANC) > 1000/mm^3
+Absolute neutrophil count < 1.5 x109/L (< 1500 cells/mm3)
+Hematologic absolute neutrophil count (ANC) >= 1.5 X 10^9/L
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Obtained within 14 weeks prior to registration on study: absolute neutrophil count (ANC) >= 1,800 cells/mm^3
+Absolute neutrophil count (ANC) >= 1.0 × 10^9/L
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) < 1,000 cells/mm^3.
+Has adequate bone marrow function defined as a hemoglobin > 9 g/dL, absolute neutrophil count (ANC) ?1.5 ×10?/L , and platelet count ?100,000/mm³. For subjects who received chemotherapy for melanoma just prior to screening for the study subject needs to have a hemoglobin > 9 g/dL, absolute neutrophil count (ANC) >2 × 10?/L, and platelet count ?100,000/mm³.
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L obtained within 14 days prior to registration
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L, performed within 28 days of treatment initiation
+Subjects with an absolute neutrophil count (ANC) < 1000 cells/mm3; growth factors may not be used to meet ANC eligibility criteria
+Absolute neutrophil count >= 1,000/mm^3
+Neutrophil count: ? 1.5 x 109/L
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) > 1,000/mm^3
+Absolute neutrophil count (ANC) greater than or equal to 1.5 x 10^9/L
+Absolute neutrophil count >= 1,000/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3 obtained =< 14 days prior to registration
+Absolute neutrophil count (ANC) ? 1000/mm3 (screening ANC should be independent of growth factor support for ? 1 week)
+Absolute Neutrophil Count >1500 cells/mm3
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1500/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
+Participants with an absolute neutrophil count (ANC) < 1000 cells/mm^3 at time of screening evaluation; growth factor may not be used to meet ANC eligibility criteria within 14 days of obtaining screening evaluation
+Absolute neutrophil count ? 1.5 × 109/L
+Absolute neutrophil count (ANC) > 1500/mm^3 (obtained =< 7 days prior to randomization)
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+and absolute neutrophil count (ANC) ? 1.5 × 10^9/L
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count >= 1.0/mm^3
+Absolute neutrophil count (ANC) > 1000/mm^3 without growth factors or transfusions
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) (neutrophil and bands) ?1.5 x 10 ^9/L
+Absolute neutrophil count (ANC) >= 1500 mL
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L without filgrastim (GCSF) support within 7 days
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1500/mm^3 obtained =<14 days prior to randomization
+Absolute neutrophil count >= 1500/mL
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count >= 1.0 x 10^9/L
+Absolute neutrophil count >= 1,500/?L
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Peripheral absolute neutrophil count (ANC) >= 1000/mm^3 and
+Absolute neutrophil count ?1,500/µL and
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3 based on complete blood count (CBC)/differential obtained within 21 days prior to study registration
+Absolute neutrophil count (ANC) >= 1,800 cells/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) > 1,500/mm^3; (patients who have bone marrow infiltration by MCL are eligible if their ANC is >= 1000/mm^3 [growth factor not allowed] or their platelet level is >= 50,000/mm^3)
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count >= 1,500
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute neutrophil count (ANC) > 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count >= 1.0 x 10^9 cells/L (growth factor use is allowed)
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count >=1.5 x 10^9/litre (L)
+Absolute neutrophil count =< 1.5 x 10^9/L
+PHASE I: Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) ? 1,000/?L
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) count >= 1,500/mm^3
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count >=1500/mL
+Absolute neutrophil count (ANC) < 0.75 x 109/L or platelet count < 50 x 109/L unless due to disease involvement in the bone marrow.
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count ?1500/?L
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute neutrophil count > 1000/microliter
+Absolute neutrophil count (ANC) 1000/mm^3
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
+Absolute neutrophil counts >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) > 0.75 x 10^9/L in the absence of growth factor in the prior 7 days
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3; blood transfusion to meet the inclusion criterion will not be allowed
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count >= 1,000/mL
+Absolute neutrophil count (ANC) ?1500/µL
+Absolute neutrophil count >= 1,500/microL
+Absolute neutrophil count >= 1,500 cells/mm^3
+Absolute neutrophil count ?1.5 ×109/L;
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) ?1.5 x 109/L.
+Absolute neutrophil count (ANC) >= 1,500
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 750/mm^3
+absolute neutrophil count (ANC) > 1000/mm3
+Absolute neutrophil count of < 1500/mm^3
+Absolute neutrophil count >= 1,500/mL
+At least 4 weeks (28 days) prior to registration: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L without growth factor support
+Absolute neutrophil count (ANC) =< 500
+Absolute neutrophil count ? 1.5 x 10^9/L.
+Absolute neutrophil count (ANC) >= 1.0 × 10^9/L (without transfusion support and without hematological growth factor support within 2 weeks of cycle 1 day 1)
+Absolute neutrophil count (ANC) > 750
+Absolute neutrophil count (ANC) < 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1000/mL
+Absolute neutrophil count >= 1,000/dL
+Absolute neutrophil counts (ANC) >= 1,500cells/mm^2
+Absolute neutrophil count (ANC) ? 1000 cells/µL
+Absolute neutrophil count (ANC) >= 1500
+Absolute Neutrophil Count ? 1500/mm3
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) <1.5 x 109/L
+Absolute neutrophil count >= 500/mm^3
+Absolute neutrophil count (ANC) < 1000 cells/mm^3
+Participants with an absolute neutrophil count (ANC) < 1500 cells/mm^3 at time of screening evaluation; growth factor may not be used to meet ANC eligibility criteria within 7 days of obtaining screening evaluation
+Absolute neutrophil count ? 1.0 × 10^9 cells/L
+Absolute Neutrophil Count (ANC) <1000 within 8 weeks prior to initial cryoablation procedure.
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (tested within 14 days prior to registration)
+Absolute neutrophil count (ANC) ?1 x 10^9/L
+Within 30 days prior to initiation of protocol treatment: Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L.
+Absolute neutrophil count > 1200
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1.0 x 10^9 /L. No transfusion or growth factor support for one week prior to labs.
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 within 30 days prior to registration
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count > 1,000 cells/mm^3 (1.0 x 10^9/L), if neutropenia is due to bone marrow involvement absolute neutrophil count must be >= 500 cells/mm^3 (0.5 x 10^9/L)
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
+Peripheral absolute neutrophil count (ANC) >= 750/m^3 (no transfusion within 7 days of enrollment)
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3 or >= 1.5 bil/L
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm3
+Absolute neutrophil count (ANC) >= 1.2 x 10^9/L
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count > 1500/mm^3
+Absolute neutrophil count >= 1,000/mm^3 (unsupported)
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count >= 1,800 cells/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3 or >= 1.5 bil/L
+Absolute neutrophil count (ANC) >= 1200/mm^3
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3 or >= 1.5 bil/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count of more than or equal to 1500/mm^3
+Absolute neutrophil count >= 1.5 X 10^9 cells/L
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) ? 1500/?L
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Obtained within 2 weeks from study entry: Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count < or equal to 1.5 x 10^9/L
+Absolute neutrophil count ? 1.5 x 10^9/L.
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count >= 1.0/mm^3
+Absolute neutrophil count (ANC) ? 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1500 cells per mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count >= 1,000/mL
+Obtained =< 7 days prior to registration: Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) > 1,000/mm^3
+Absolute neutrophil count >= 1000/mm^3
+Absolute neutrophil count >= 1.2 x 10^9/L
+STEP 2 ENROLLMENT AND RANDOMIZATION: absolute neutrophil count (ANC) >= 1,500/mm^3 within 3 weeks of study entry
+Absolute neutrophil count (ANC) =< 1.0
+Neutrophil count >= 1.5 x 10^9/l
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute Neutrophil Count (ANC) ? 1.5 x 109/L
+Absolute neutrophil count >= .750 x 10^9/L
+Neutrophil < 1.0 x 10^9/L
+Absolute neutrophil count (ANC) ? 1.0 (1000/mm3)
+Absolute neutrophil (segmented and bands) count (ANC) >= 1.0 x 10^9/L
+Absolute neutrophil count (ANC) < 1 x 10^9/L
+Patient has an absolute neutrophil count of < 1000 within 5 days before enrollment
+Absolute neutrophil count (ANC) < 1500/mL
+Absolute neutrophil count >= 1,000 (1.0 x 10^9/L)
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,250/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) greater than 1000/mm^3
+Absolute neutrophil count (ANC) > 1000
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1000
+Absolute neutrophil count >= 1,000/mL
+Absolute neutrophil count (ANC) >= 1.5 X 10^9/L
+Within one week of study entry: Absolute neutrophil count (ANC) >= 1000 cells/mm^3
+Absolute neutrophil count >= 1000 cells/mm^3
+Absolute neutrophil count (ANC) >= 1,000 cells/mm^3
+Prior to day 1 of brentuximab vedotin, patients must again meet the following criteria:\r\n* Hemoglobin >= 8 g/dL\r\n* Absolute neutrophil count (ANC) >= 1,000 cells/mm^3\r\n* Platelet count >= 75,000/mm^3\r\n* Maximum Child-Pugh score of 5\r\n* Creatinine clearance > 50 mL/min via Cockcroft and Gault
+Patients who have had count recovery (absolute neutrophil count [ANC] > 500,000/mm^3; non transfused platelet count over 30,000/mm^3) and are at least 30 days after induction and/or transplantation but no more than 120 days post transplant
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 X 10^9/L
+Absolute neutrophil count (ANC) > 1,500 (growth factors permitted)
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,500/mm^3 obtained =< 14 days prior to randomization
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500/mm^3) may be supported by transfusion and/or hematopoetic growth factors
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Neutrophil count ? 1,500 /mm3
+Absolute neutrophil count (ANC) >= 1500/ml
+Absolute neutrophil count >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1000 cells/mm^3
+Neutrophil count >= 1000 prior to biopsy
+Within 14 days prior to registration: Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count (ANC) > 1000/mm^3
+Absolute neutrophil count > = 1000 /mm³
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) >= 1.0 X 10^9/L
+Absolute neutrophil count >= 1,500
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (growth factors not permitted to make eligible)
+Absolute neutrophil count (ANC) >= 1.5 X 10^9/L
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >1000/?L and Platelet count > 25,000/?L
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count >= 500/mm^3
+Absolute neutrophil count >= 1000/mL (obtained =< 14 days prior to registration)
+Absolute neutrophil count (ANC) > 1.5 x 10^9/L
+Absolute neutrophil (segmented and bands) count (ANC) >= 1.0 x 10^9/L
+Absolute neutrophil count < 500 at the time of brachytherapy
+Absolute neutrophil count >= 1,500/mm^3
+Has an absolute neutrophil count <1.0x10^9/L within 14 days before enrollment
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1000/microliter
+Absolute neutrophil count (ANC) >= 1,800 cells/mm^3
+Absolute neutrophil count greater than 1000/mm^3
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1500/mL
+Absolute neutrophil count (ANC, calculated as the absolute number of neutrophils and bands) >= 1.5 x 10^9 cells/L
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1,000/mL
+Absolute neutrophil count >= 1,000/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L or at least 1,500/mm^3 or at least 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1.0 x 109/L
+Absolute neutrophil count >= 1,000/mL
+Absolute neutrophil count >= 1,000/mm^3
+CARBOPLATIN AND PACLITAXEL ARMS: absolute neutrophil count >= 1,500/mL
+SORAFENIB ARM: absolute neutrophil count >= 1,000/mL
+Absolute neutrophil count (ANC) >= 1000
+Absolute neutrophil count >= 1,500/mm^3
+EXPANSION COHORT ONLY: Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count > 750 cells/mm^3
+Absolute neutrophil count (ANC) ?1.5 x 10^9/L
+Absolute neutrophil count (ANC) > 1000
+Patient has an absolute neutrophil count of less 1000 within 14 days before enrollment
+Absolute neutrophil count >= 1,500 /mm^3
+Absolute neutrophil count (ANC) ?1500 cells/mm3
+Absolute neutrophil count >= 500/mm^3
+Absolute Neutrophil Count (ANC) < 1,500/mm^3
+Absolute lymphocyte count < 800/mm^3
+Absolute neutrophil count (ANC) >= 1,800 cells/mm^3
+Absolute neutrophil count (ANC) ? 1.5 x 109/L
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L (>= 1000 per mm^3)
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500 per mm^3)
+Adequate hematological function defined by white blood cell (WBC) count ?3 × 10^9/L; absolute neutrophil count (ANC) ?1.5 × 10^9/L; lymphocyte count ?0.5 × 10^9/L; platelet count ?100 × 10^9/L; and hemoglobin ?9 g/dL (may have been transfused).
+Absolute neutrophil count (ANC) >= 1,200 cells/mm^3
+Within 8 weeks of randomization: Absolute neutrophil counts >= 1,500 cell/mm^3
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count ANC ?1.5 x 109/L (?1500/mm3)
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (> 1500 per mm^3), obtained within 14 days prior to first treatment
+Absolute neutrophil count (ANC) ? 1.5 × 109/L
+Absolute neutrophil count (ANC) < 750 cells/mm^3 (0.75 x 10^9/L)
+Absolute neutrophil count ?1.5 x 109/L,
+Absolute neutrophil count (ANC) ? 1500/?L (without intervention, e.g., G-CSF)
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (>= 1500 per mm^3)
+Absolute neutrophil count (ANC) >= 1000 cells/mm^3
+Absolute neutrophil count >= 1,000/mL
+Absolute neutrophil count less than 1500 per microliter.
+Absolute neutrophil count (ANC) >= 1500/mL
+Absolute neutrophil count (ANC) >= 1200/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1000 cells/mm^3 and platelet count >= 60 K when maintenance lenalidomide is started (day 100 post-transplant)
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count ? 1500/mm3
+Absolute neutrophil count ? 1000/mm3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count of > 1500 per microliter
+Absolute neutrophil count (ANC) > 750/mm^3
+Absolute neutrophil count (ANC) <1,000/?L (1.0 X 109/L)
+Absolute neutrophil count (ANC) >= 1.5 x 10^9 cells/L
+Absolute neutrophil count (ANC) of >= 1,500/microliters within 90 days prior to registration
+Absolute neutrophil count (ANC) > 500/mm^3
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3
+No unexplained absolute eosinophil count > 1.5x10^9/L
+Patient has an absolute neutrophil count of < 1.2 x 10^9/L.
+Absolute neutrophil count (ANC) > 1000 unless impairment due to organ involvement by lymphoma
+Neutrophil count > 1,000/mm3
+Absolute neutrophil count (ANC) ?1.0 × 109/L
+Absolute neutrophil count ? 1,000 cells/mm3
+Subjects with an absolute neutrophil count (ANC) >500/?L at Screening.
+Absolute neutrophil count (ANC) ? 1500/mm3 (?1.5× 109/L).
+Absolute neutrophil count (ANC) >= 750/mm^3
+Absolute Neutrophil Count of at least 1.5 x 109/L
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute Neutrophil Count 75 x 10(9)/L;
+Absolute neutrophil count (ANC) equal or greater to 1000 without growth factor support for at least 5 days
+Absolute neutrophil count (ANC) of 750
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count >= 1,000/mm^3 (unsupported)
+Absolute neutrophil count >= 1.5 x 10^9/L
+Neutrophil count > 1000/mm^3
+Evidence of myeloid engraftment (absolute neutrophil count ?0.5 x 10^9/L)
+Absolute neutrophil count (ANC) >= 1,000 cells/mm^3 (without platelet transfusion or myeloid growth factor support within two weeks of screening)
+absolute neutrophil count >1,500/mm3
+Absolute neutrophil count (ANC) > 1000 cells/ml
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) ?1.0 ×109/L
+Absolute neutrophil count ?1,000/?L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Hematological: absolute neutrophil count (ANC) > 1,500 cells/mm^3, platelet > 100,000 cells/mm^3, hemoglobin > 9.0 g/dL
+Absolute neutrophil count (ANC) ? 1,000/?L
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Subjects must have adequate bone marrow function as assessed by the following: hemoglobin >=9.0 g/dL or >=5.6 mmol/L, absolute neutrophil count (ANC) >=1.500/mm^3 or >=1.5 x 10^9/L (CTCAE Grade <=1), platelet count >= 100000/mm^3 or >=100 x 10^9/L
+Absolute neutrophil count (ANC) < 1500/ml
+Hematologic function: Absolute neutrophil count (ANC) > 500/?L and platelet count > 25,000/?L without transfusion
+Absolute-neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 500/mm^3
+Absolute neutrophil count (ANC) > 1500/mm^3
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1,000
+Absolute neutrophil count (ANC) ? 1500 (1.5 × 109/L) cells/mm3;
+Hematological: Absolute neutrophil count (ANC) ? 1.5 x 10^9/L, platelet ? 100 x 10^9/L, hemoglobin ? 9 g/dL
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) > 1,000 cells/mm^3
+Absolute neutrophil count ? 1,000/?L;
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Hematological: absolute neutrophil count (ANC) ?1500 cells/mm^3, platelet ? 100,000 cells/mm^3, hemoglobin ? 9.0 g/dL
+Absolute neutrophil count (ANC) ? 1.5 x 10^9/L
+Absolute neutrophil count (ANC) ? 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,200/mm^3
+Absolute neutrophil count (ANC) >= 1,500 cells/m^3
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute Neutrophil Count (ANC) < 1.5 x 109/L Cardiac function:
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Absolute neutrophil count (ANC) >= 1,000 cells/mm^3
+Absolute neutrophil count: >= 1,500/mm^3
+Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) > 1500 cells/mm^3, platelet > 100,000 cells/mm^3, hemoglobin > 9 g/dL
+Absolute neutrophil count (ANC) > 1.5 x 109/L
+Absolute neutrophil count (ANC) ?1500/?L
+Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) > 1,000/mm^3; (patients who have bone marrow infiltration by MCL are eligible if their ANC is 500/mm^3 [growth factor allowed] or their platelet level is equal to or > than 30,000/mm^3)
+Absolute neutrophil count: >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Inadequate bone marrow function (Absolute neutrophil count (ANC) < 1,500 cells/mm3; Platelet count < 100,000 cells/mm3; Hemoglobin < 9.0 g/dL)
+Absolute neutrophil count of > 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 0.75 X 10^9/L
+Absolute neutrophil count >= 1500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1500
+Absolute neutrophil count (ANC) must be > 750/mm^3 (unless due to underlying disease in which case there is no grade restriction)
+Absolute neutrophil count (ANC) < 1.0 x 109/L
+Absolute Neutrophil Count (ANC) ? 1500 cells/mm3
+Absolute neutrophil count (ANC) >= 1,000 cells/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (1500/mm^3)
+Absolute Neutrophil Count (ANC) ? 1,500/microL
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (1500/mm^3)
+Absolute neutrophil count (ANC) > 1,000 cells/dL (1.0 x 109/L)
+Absolute neutrophil count (ANC) of >= 500/?L
+Absolute neutrophil count >= 1500/mm^3
+Absolute Neutrophil Count > 1,500/mm3
+Absolute neutrophil count (ANC) ? 1500/µL (? 1.5 x 103/µL)
+An absolute neutrophil count of more than or equal to 1500/mm^3
+Absolute neutrophil count of >= 1.2 x 10^9/L
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count >= 1.2 x 10^9/L
+TREATMENT: Absolute neutrophil count greater than 1500/mm^3
+Absolute neutrophil count >= 1,500/microliters
+Absolute neutrophil count (ANC) >= 1500 cells/mm3 without growth factor support
+Absolute neutrophil count ?1,500/?L
+SELUMETINIB ARM: Absolute neutrophil count (ANC) < 1.5 x 10^9/L (1500 per mm^3)
+Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count >= 1500 neutrophils/mm^3
+RECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Absolute neutrophil count >= 1,000/mm^3
+NON-PROGRESSED DIPG (STRATUM 2): Absolute neutrophil count >= 1,000/mm^3
+Absolute neutrophil count (ANC) <1,500/?L
+Absolute neutrophil count >= 1.5 x 10^9/L
+Within 14 days prior to first study treatment: Absolute neutrophil count (ANC) >= 1500/10^9 dL
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3
+Absolute neutrophil count (ANC) >=1.5*10^9/L.
+Absolute neutrophil count <1000/mL
+Absolute neutrophil count >= 1,500/microliters
+Absolute neutrophil count > 1.5 x 10^9 cells/mm^3, +/- 7 days from date of ICF signing
+Absolute neutrophil count >= 1500 neutrophils/mm^3
+Absolute neutrophil count (ANC) ? 1,500 cells/mm3 or ? 1000 cells/mm3 if secondary to bone marrow involvement by disease.
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count (ANC) must be >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L, unless due to bone marrow involvement with lymphoma
+Absolute granulocyte count (ANC) >= 1.2 x 10^3/mm^3
+Absolute neutrophil count (ANC) < 1500/mm^3
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) less than 1,000 /mm3
+Absolute neutrophil count >= 2,000/mm^3
+Platelet count ? 100 x 109/L, absolute neutrophil count (ANC) ? 1.5 x 109/L, Hemoglobin ? 9 g/dL.
+Absolute neutrophil count ? 1,500/mm3 (not supported by growth factors in the preceding 21 days);
+Absolute neutrophil count (ANC) ? 1500/mm3
+Absolute neutrophil count (ANC) greater than or equal to 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3
+Hemoglobin ? 7.5 g/dL, - Absolute neutrophil count ? 1.0 x 109/L (1000/mm3), - Platelets ? 50,000/?L
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) ? 1,000/?l
+Absolute neutrophil count >= 1,500 mm^3
+Peripheral absolute neutrophil count (ANC) >= 1000/mm^3; \r\n* Note: must be > 7 days from use of hematopoietic growth factor or 21 days from pegfilgastrim
+Absolute neutrophil count (ANC) >= 1.5 X 10^9/L
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count ? 1500/mm3
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
+Absolute neutrophil count (ANC) ? 1500 cells/mm3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count 1500 cells/mm3 (1.5 x 109/L)
+Absolute neutrophil count <1.5 x 10^9/L.
+Absolute neutrophil count (ANC) ? 1500 cells/mm3;
+Absolute neutrophil count (ANC) > 1000/mm^3
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count (ANC) ? 1500 cells/mm3.
+Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) <1,500/mm3
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) < 1500 / mm^3
+Absolute neutrophil count (ANC) > 500/mm^3
+Absolute neutrophil count (ANC) < 1,500/mm3.
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) ? 1500/?L and platelet count ? 75,000/?L.
+Absolute neutrophil count ? 1.5 x 10^9/L within 14 days prior to randomization.
+Absolute neutrophil count of 1500 or greater
+Absolute neutrophil count (ANC) >= 1,000 cells/mm^3
+Absolute neutrophil count (ANC) < 1,000/mm3 without growth factor support within 7 days prior to testing
+Absolute neutrophil count (ANC) ? 1,500/µL (without growth factors)
+Absolute neutrophil count >=1,500 per cubic millimeter (/mm^3), not supported by growth factor
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) ? 1,000/?L, platelets ? 100,000/?L.
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count ? 1500/mm3
+Absolute neutrophil count (ANC) ³ 1.5 × 109/L (1,500/mm3)
+Absolute neutrophil count at least 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,000/mm^3
+Does the subject have an absolute neutrophil count (ANC) ? 1500/mm3?
+Does the subject have an absolute lymphocyte count ? 500/mm3?
+Absolute neutrophil count (ANC) >=1.2x10^9/L
+Absolute neutrophil count (ANC) ?1.5 x 10?/L
+Absolute neutrophil count (ANC) >= 1500
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1.5 x 10^9 cells/L
+Absolute Neutrophils Count (ANC) ? 1.5 x 109/L
+Absolute neutrophil count > 1000 cells/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) < 1,500 per mm3
+Absolute neutrophil count (ANC) ? 1.5 x 109/L
+Absolute neutrophil count (ANC) ?1.5 x 109/L.
+Absolute neutrophil count (ANC) >= 1500/?L obtained =< 7 days prior to registration
+Absolute lymphocyte count ?0.75 x 10^3/µl
+Absolute neutrophil count (ANC) >= 1500/mm^3 (filgrastim [G-CSF] is allowed)
+Neutrophil count of > 1500 cell/mm^3
+Absolute Neutrophil count (ANC) ? 1.0 x 109/L without daily use of myeloid growth factor; and
+Absolute neutrophil count > 750/mm^3
+Absolute neutrophil count (ANC) > 1500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1000/?L
+Whole Blood Cells (WBC) ?3.0 x 10?/L, Absolute neutrophil count (ANC) ?1.5 x 10?/L and platelet count ?100 x 10?/L
+Absolute neutrophil count (ANC) ? 1.0 x 109/L
+Absolute Neutrophil Count (ANC) ? 1.5 x 109/L.
+Absolute neutrophil count (ANC) < 1,500 per mm3
+Absolute neutrophil count (ANC) >= 1,500cells/mm^3
+Absolute neutrophil count (ANC) greater than or equal to (?) 1000/microliter
+Peripheral absolute neutrophil count (ANC) ? 1.5 x 109/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) ? 1.5 x 109/L
+Absolute neutrophil count ? 1500 cells/mm3.
+Absolute neutrophil count (ANC) ?1.0 x 109/L
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count >= 500/mm^3
+Absolute neutrophil count (ANC) ? 1.5 x 10^9/L and platelet count ?100 x 10^9/L
+The patient has adequate bone marrow reserve: • Absolute neutrophil count (ANC) > 0.5 × 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 cells/mm^3
+Absolute neutrophil count > 1500/mm^3
+Cohort A: Absolute neutrophil count greater than 1500/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count ? 500/µL, with or without cytokine support
+Absolute neutrophil count (ANC) ? 1,500/µL
+Absolute neutrophil count (ANC) ? 1500/µL
+Absolute neutrophil count >= 1,500/?L
+Absolute neutrophil count (ANC) >= 1500/mm^3 (1.5 x 10^9/L) (participants receiving transfusion, erythropoietin, or myeloid growth factor support will be eligible for this study)
+Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count greater than 1000/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute Neutrophil Count ? 1500/mm3
+Absolute neutrophil count (ANC) ? 1000/mm³ within 21 days prior to randomization. Screening ANC should be independent of growth factor support for ? 1 week.
+Absolute neutrophil count >= 1,000/mL
+Absolute neutrophil count >/= 1,200/mm3
+Absolute neutrophil count >= 1,000/mm^3
+Absolute neutrophil count of > 1,500 cell/mm^3
+Absolute neutrophil count (ANC) ? 1.5 x 10^9/L;
+Absolute neutrophil count (ANC) >= 1200/mm^3
+Absolute neutrophil count >= 1,200/µL
+Absolute neutrophil count (ANC) >= 1,000 cells/dL (1.0 x 10^9/L) (growth factors cannot be used within 7 days of first drug administration)
+Absolute neutrophil count (ANC) ?1.5 x 10^9/L
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count >1,500 cells/mm3
+Absolute neutrophil count (ANC) >= 1,500
+Absolute neutrophil count (ANC) of ?1.0x109/L.
+Absolute neutrophil count (ANC) < 1,000/?L
+Absolute neutrophil count (ANC) >= 1.5 X 10^9/L
+Absolute Neutrophil Count < 1.000/µl.
+Absolute neutrophil count (ANC) =< 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1,000
+Absolute neutrophil count >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count >= 1,000/mm^3
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count >= 1500 cells/mm^3
+absolute neutrophil count > 1500/mm^3
+absolute lymphocyte count > 500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 X 10^9/L
+Absolute neutrophil count (ANC) >= 1,500/mm3
+Absolute neutrophil count ? 1.0 × 10^9/L within 21 days prior to randomization
+Absolute neutrophil count >= 1,500/mm^3
+Aplastic anemia with absolute neutrophil count (ANC) < 1000 and transfusion dependent after they failed immunosuppression therapy
+Absolute neutrophil count (ANC) >= 1000mm^3
+Absolute neutrophil count >= 1,500/mm^3
+absolute neutrophil count (ANC) >=1.5*10^9/L
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute lymphocyte count >= 200/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1,500/mL
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 750/mm^3
+Absolute neutrophil count >1000 cells/mm^3 without growth factors for 7 days.
+Absolute neutrophil count (ANC) < 1,000/µL (1.0 x 109/L)
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1500 mm^-3
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1500 cells/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9 /L (>= 1500 per mm^3)
+Absolute neutrophil count (ANC) >= 1200/mm^3
+Absolute neutrophil count greater than 1500/mm^3 without transfusion or cytokine support
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1.0 x 10^9/L (without growth factor support)
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Neutrophil count ? 1,000/mm3
+Absolute neutrophil count (ANC) < 1,000/mm^3 (International System of Units [SI] units 109/L)
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3 (International System of Units [SI] units 1.5 x 10^9/L)
+Neutrophil count of >= 0.5 x 10^9/L
+Absolute neutrophil count (ANC) > 1500/mm^3
+Absolute neutrophil count (ANC) > 1000/mm^3 unless deemed likely related to lymphoma involvement in the bone marrow where the minimum ANC allowable will be 500/mm^3
+Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count greater than 1000/mm^3 without the support of filgrastim
+Absolute neutrophil count (ANC) >= 1500 mm^-3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L (growth factor support is allowed to reach this goal)
+Absolute neutrophil count >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) 1500/mm^3; blood transfusion to meet the inclusion criteria will not be allowed
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,100 cells/mm^3
+Absolute neutrophil count (ANC) >= 1,500/?L unless due to marrow involvement by lymphoma
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) > 1500 mm^3 for 14 days prior to registration
+Participants with an absolute neutrophil count (ANC) < 500
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) > 1500
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L without growth factor support
+Absolute neutrophil count of at least 1.5 × 109/L,
+Absolute neutrophil count >= 1,500/microliter
+Absolute neutrophil count (ANC) ?1.5 × 10^9/liter (L);
+Absolute neutrophil count (ANC) ? 1,000 cells/mm3
+Absolute neutrophil count (ANC) > 1500/mm^3
+Absolute neutrophil count (ANC) > 1500/mm^3
+Neutropenia as defined by an absolute neutrophil count (ANC) of < 1000 cells/mm
+Absolute neutrophil count (ANC) >= 1,500 cells/L
+Absolute neutrophil count less than 200/microliter
+Neutropenic patient with absolute neutrophil count (ANC) less than 1000 cells/mm^3
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil counts (ANC) ? 1,500/mm3
+Subjects with an absolute neutrophil count (ANC) of equal to or higher than 0.5 x 10^9/L at the screening visit
+Absolute neutrophil count (ANC) > 1 x 10^9/L
+Absolute neutrophil count >= 1,500
+Absolute neutrophil count (ANC) 1500/mm^3
+Absolute neutrophil count >= 1,500 cells/mm^3
+Absolute neutrophil count (ANC) ? 1,500/mm3
+Absolute neutrophil count >= 1,000/mm^3
+Absolute neutrophil count (ANC) >= 1200/mm^3 (>= 1.2 x 10^9/L)
+Absolute neutrophil count (ANC) >= 1500, unless felt to be secondary to underlying mantle cell lymphoma
+Absolute neutrophil count >= 500 cells/mm^3 (0.5 x 10^9/L); growth factor allowed to achieve
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count <1000/mL
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) > 1500/mm^3
+Absolute neutrophil count: >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 0.75 x 10^9/L
+Hematopoietic engraftment as evidenced by recovery of the absolute neutrophil count to greater than 500/mm^3 for > 3 days without filgrastim (G-CSF) support and within 40 days of transplant (i.e. complete blood counts [CBCs] obtained 3 or more days apart while off of G-CSF must demonstrate an absolute neutrophil count > 500/mm^3); if absolute neutropenia is not achieved due to a non-myeloablative transplant, the patient can be enrolled on day +21 to +40
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) > 1000/mm^3 without growth factors or transfusions
+Absolute neutrophil count >= 1500/mm^3
+Absolute neutrophil count >= 750/mm^3
+Absolute neutrophil count >= 1.5 K/mm^3
+Patient currently with neutropenia (absolute neutrophil count <1000) within 6 weeks screening
+Anticipated or documented prolonged neutropenia (absolute neutrophil count [ANC] < 500/mm^3 [0.5 x 10^9/L]) at baseline or likely to develop within 3 to 5 days and lasting for at least 7 days due to:
+Absolute neutrophil count < 1.5 x 10^9/L (1500/mm^3)
+Absolute neutrophil count (ANC) ? 1,500 x10^9/L
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count: >= 750/mm^3 within 90 days before enrollment
+Absolute neutrophil count (ANC) >= 1500/mm^3
+Hematological: Total absolute phagocyte count ?1000/?L
+Absolute neutrophil count >= 1,500/microliter
+Absolute neutrophil count >= 1,500/microliter
+Absolute neutrophil count >= 1,500/microliter
+Neutrophils (absolute neutrophil count [ANC]) >= 1,500/microliter
+Absolute neutrophil count >= 1,500/microliter
+Absolute neutrophil count >= 1,500/microliter
+Absolute neutrophil count >= 1,500/microliter
+Absolute neutrophil count (ANC) > 0.75 x 10^9/L
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Patients must have or be anticipated to have neutropenia (absolute neutrophil count [ANC] < 0.5 x 10^9/L) (75) for >= 7 days as a result of treatment of their AML/MDS
+Absolute neutrophil count (ANC) >= 1,000 cells/mm^3
+Absolute neutrophil count >= 1,500/microliter
+Required prior to infusion of ATLCAR.CD30 cells: Absolute neutrophil count (ANC) >= 500 cells/mm^3 for 3 consecutive days
+Absolute neutrophil count >= 1,500/microliter
+Absolute neutrophil count (ANC) < 1,000 cells/mL
+Absolute neutrophil count >= 1,500/microliter
+Absolute neutrophil count >= 1,000/microliter
+Absolute neutrophil count >= 1,500/microliter
+Total neutrophil count > 1,500/mm^3
+Absolute neutrophil count >= 1,500/microliter obtained =< 45 days prior to randomization
+Absolute Neutrophil Count (ANC) > 500/?l and platelet count >50,000/?l
+Absolute neutrophil count >= 1,500/microliter
+Absolute neutrophil count (ANC) >= 1 x 10^9/L
+Absolute Neutrophil Count (ANC) ? 1.5 x 109/L or ? 1.0 x 109/L (with bone marrow involvement with DLBCL)
+Absolute Neutrophil Count ? 1500/ mm3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Measured within 28 days prior to administration of study treatment: Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count greater than 1500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1,500/mm^3
+Absolute neutrophil count ³ 1.5 x 109/L
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L (> 1000 per mm^3)
+Absolute lymphocyte count ? 500/mm3
+Absolute neutrophil count ? 1000/mm3
+Absolute neutrophil count (ANC) of =< 1000
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count >= 1,500/microliter
+Absolute neutrophil count (ANC) > 750 cells/mm^3
+Within 14 days prior to study entry: Absolute neutrophil count (ANC) > 1000/mm^3
+- Neutrophil count of > 1000/mm3
+Absolute neutrophil count (ANC) >= 1000/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,500/mm^3, obtained within 14 days prior to C11-AMT PET scan
+Absolute neutrophil count ?1.50 x 109/L
+Neutrophil count > 1,000/mm^3
+Absolute neutrophil count (ANC) >= 1.5 X 10^9/L (evaluated within 28 days of\r\nrandomization)
+Absolute neutrophil count >= 1.5 K/cu mm
+Absolute neutrophil count >= 1.5 K/cu mm
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1,000 cells/mm^3 without transfusion support > 7 days prior to registration
+Absolute neutrophil count (ANC) ?1.5 x 109/L (in absence of growth factor support)
+Baseline safety laboratory abnormalities: ANC (absolute neutrophil Count) < 1000 cells/mm3, platelet count < 25,000 cells/mm3, hemoglobin < 8.0 g/dL, AST (aspartate transaminase) or ALT (alanine transaminase) > 5 x ULN (upper Limit of normal), bilirubin > 2.5 x ULN
+Peripheral absolute neutrophil count (ANC) >= 1500/mm^3
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) ? 500/?l and platelets ? 20000/?l (unsupported by transfusions).
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L, within 2 weeks prior to study start
+- Neutrophil count of > 1000/mm3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/l
+Absolute neutrophil count < 1,500/mm^3
+Absolute neutrophil count (ANC) ?1500/mm3 (?1.5×109/L)
+Absolute neutrophil count > 1,500 cells/mm^3*
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count > 1000/mm3
+Absolute neutrophil count (ANC) >= 1,500/mm^3, performed within 28 days prior to registration
+Absolute neutrophil count > 750
+Absolute neutrophil count (ANC) >= 1,500/mm^3
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
+Absolute neutrophil count > 1,500/µL
+Absolute neutrophil count >= 1.5 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.0 x 10^9/L
+Absolute neutrophil count (ANC) >= 1.2 X 10^9/L
+Absolute neutrophil count (ANC) greater than or equal to (>=) 1500 per cubic millimeter (/mm^3).
+Absolute Neutrophil Count (ANC) ? 1.5 x 10E9/L
+Neutrophil count <1.5 x 109/L
+Absolute neutrophil count < 1.0 x 10^9/L
+Absolute neutrophil count (ANC) ?1.5 x 109/L
+Bone marrow reserve consistent with absolute neutrophil count (ANC) ?1.5*10^9/L; platelet count ?100*10^9/L; hemoglobin (Hgb) ?9 g/dL.
+Absolute neutrophil count (ANC) ? 1.5x10^9/L;
+absolute neutrophil count ? 1,500/mm3,